Purchase this article with an account.
Eleonora M. Lad, Adam Prickett, Richard Lin; Comparison of Outcomes of Argon vs. Pascal Laser for Diabetic Retinopathy. Invest. Ophthalmol. Vis. Sci. 2011;52(14):1285.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To assess the efficacy and outcomes of Pascal laser versus Argon laser for focal and panretinal photocoagulation (PRP) in the treatment of diabetic retinopathy.
Retrospective chart review of patients at the Palo Alto VA who have undergone laser (focal or PRP) treatment for diabetic retinopathy between 2005 and 2008 and who had at least one year follow up. Patients were identified by searching ICD-9 codes for diagnoses involving diabetic retinopathy, CPT codes for focal or PRP laser treatment and by reviewing the laser log books. The study endpoints were change in visual outcome, central retinal thickness (CMT) by OCT, regression of neovascularization and number of additional intervention after initial laser treatment measured at early (3-6 months) and late (one year) follow-up.
111 charts of Argon-treated patients and 28 charts of Pascal-treated patients were reviewed. There was no significant difference between Pascal laser treatment and argon laser treatment in ability to prevent visual loss, resolution of macular edema and neovascularization of the disc/elsewhere (NVD/NVE) at the early and late follow-up (p>0.05). There was a tendency for higher frequency of some additional treatments (laser, and intravitreal injections but not surgeries) following Pascal laser treatments than following Argon treatments.
Pascal laser treatment is as effective as the traditional argon laser treatment in preventing visual loss and in resolution of macular edema and NVD/NVE but may be associated with an increased need for additional treatments.
This PDF is available to Subscribers Only